PT - JOURNAL ARTICLE AU - Shoer, Saar AU - Karady, Tal AU - Keshet, Ayya AU - Shilo, Smadar AU - Rossman, Hagai AU - Gavrieli, Amir AU - Meir, Tomer AU - Lavon, Amit AU - Kolobkov, Dmitry AU - Kalka, Iris AU - Godneva, Anastasia AU - Cohen, Ori AU - Kariv, Adam AU - Hoch, Ori AU - Zer-Aviv, Mushon AU - Castel, Noam AU - Zohar, Anat Ekka AU - Irony, Angela AU - Geiger, Benjamin AU - Hizi, Dorit AU - Shalev, Varda AU - Balicer, Ran AU - Segal, Eran TI - Who should we test for COVID-19? A triage model built from national symptom surveys AID - 10.1101/2020.05.18.20105569 DP - 2020 Jan 01 TA - medRxiv PG - 2020.05.18.20105569 4099 - http://medrxiv.org/content/early/2020/05/21/2020.05.18.20105569.short 4100 - http://medrxiv.org/content/early/2020/05/21/2020.05.18.20105569.full AB - The gold standard for COVID-19 diagnosis is detection of viral RNA in a reverse transcription PCR test. Due to global limitations in testing capacity, effective prioritization of individuals for testing is essential. Here, we devised a model that estimates the probability of an individual to test positive for COVID-19 based on answers to 9 simple questions regarding age, gender, presence of prior medical conditions, general feeling, and the symptoms fever, cough, shortness of breath, sore throat and loss of taste or smell, all of which have been associated with COVID-19 infection. Our model was devised from a subsample of a national symptom survey that was answered over 2 million times in Israel over the past 2 months and a targeted survey distributed to all residents of several cities in Israel. Overall, 43,752 adults were included, from which 498 self-reported as being COVID-19 positive. The model provides statistically significant predictions on held-out individuals and achieves a positive predictive value (PPV) of 46.3% at a 10% sensitivity. As our tool can be used online and without the need of exposure to suspected patients, it may have worldwide utility in combating COVID-19 by better directing the limited testing resources through prioritization of individuals for testing, thereby increasing the rate at which positive individuals can be identified and isolated.Competing Interest StatementThe authors have declared no competing interest.Funding Statementno external funding was receivedAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesModels and tables of de-identified, aggregated data are available at https://github.com/hrossman/Covid19-Survey. https://github.com/hrossman/Covid19-Survey